Research
Hormonal
Bariatric surgery (RYGB, VSG) and GLP-1R agonists share common neural targets in the brainstem (NTS, lPBN, CeA) and hypothalamus, suggesting overlapping mechanisms of action despite different peripheral origins.
Bariatric surgery and GLP-1 medications both work by activating specific brain pathways that reduce hunger and food intake. This shared mechanism explains why both are effective for severe obesity, even though one is surgical and the other is pharmacological.
GoodSupportsHIGH confidence
common denominator between GLP-1R agonists and bariatric surgery is that they suppress food intake by targeting the brain... RYGB... leads to the same central pattern of neuronal activation as activating GLP-1R-expressing and OXR-expressing vagal afferents in mice
Why this rating
Based on comparative studies of neural activation patterns in rodent models.
Source
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Mohammed K. Hankir et al. · Pflügers Archiv - European Journal of Physiology · 2024
DOI 10.1007/s00424-024-03047-3
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide, liraglutide) suppress food intake and induce weight loss by targeting distinct neural pathways in the brainstem (NTS, AP, LC, VTA) and hypothalamus, rather than solely relying on peripheral vagal signaling.Good
- Activation of the Area Postrema (AP) by GLP-1R agonists induces aversion (nausea) but is not necessary for appetite suppression, which is mediated by other brainstem regions like the Nucleus Tractus Solitarius (NTS).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →